This application is a 6 month collaborative project with VASGEN Ltd to develop and characterise prototype antibody inhibitors of the ADAMTS-7 protease. Vasgen will licence its antibody technology to UH to develop the antibodies and characterise them biochemically and functionally in vitro. the project could lead to further collaborative studies aimed to develop a therapeutic lead and clinical strategy.
|ADAMTS-7 Inhibition In CAD
|Effective start/end date
|1/06/22 → 31/12/22
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.